Results 71 to 80 of about 901 (171)

Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline‐recommended ...
Erik Sörstedt, George Nduva, Fredrik Månsson, Åsa Mellgren, Johanna Repits, Eva Fernvik, Adam Stubbs, Melanie Schroeder, Johanna Brännström, Christina Carlander   +9 more
wiley   +1 more source

Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient

Journal of the International Association of Providers of AIDS Care, 2017
We report the first identified case of suspected iatrogenic adrenal insufficiency after an interlaminar injection of triamcinolone acetonide while on concomitant Stribild (elvitegravir 150 mg/cobicistat 150 mg/tenofovir disoproxil fumarate 300 mg ...
Chanie Wassner PharmD, BCCCP, Sutapa Maiti MD, Kurt Kodroff MD, MMM, Henry Cohen MS, PharmD, FCCM, BCPP, BCGP   +3 more
doaj   +1 more source

Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Zoliflodacin is a first‐in‐class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug‐resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase ...
Alison Luckey, Kajal B. Larson, Noha Rayad, Markus Heep, Sophie Delhomme, Gabrielle Kornmann, John P. Mueller, John P. O'Donnell, Seamus O'Brien, Rainard Fuhr, Jean‐Yves Gillon   +10 more
wiley   +1 more source

Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 606-611, February 2026.
Mitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
Annemieke M. Peters van Ton, Nielka P. van Erp, Annenienke C. van de Ven, Janneke E. W. Walraven, Loek A. W. de Jong   +4 more
wiley   +1 more source

Polypharmacy in HIV: Rethinking what counts and why it matters

HIV Medicine, Volume 27, Issue 2, Page 186-199, February 2026.
Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran, Alan Winston, Catia Marzolini, Saye Khoo, Marta Boffito, Nadia Naous, Caroline A. Sabin   +6 more
wiley   +1 more source

Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV [PDF]

, 2020
OBJECTIVE: To evaluate the pharmacokinetics of tenofovir alafenamide (TAF) 10 mg with cobicistat and 25 mg without boosting in pregnant and postpartum women with HIV and to characterize TAF placental transfer and infant washout pharmacokinetics.
Mark Mirochnick, George, Kathleen, Kayla Denson, Richard Haubrich, Best, Brookie M, David E. Shapiro, Barr, Emily, Cielo, Mikhaela, Haubrich, Richard, Denson, Kayla, Jeremiah D. Momper, Mikhaela Cielo, Stek, Alice M, Weinberg, Adriana, Rooney, James F, Emily Barr, Kathleen George, Pinilla, Mauricio, Capparelli, Edmund V, Mirochnick, Mark, James F. Rooney, Momper, Jeremiah D, Shapiro, David E, Alice M. Stek, Smith, Elizabeth, Kittipong Rungruengthanakit, Mauricio Pinilla, Nahida Chakhtoura, Deville, Jaime G, Adriana Weinberg, Kristina M. Brooks, Rowena Espina, Espina, Rowena, Jaime G. Deville, Irma L. Febo, Brookie M. Best, Elizabeth Smith, Febo, Irma L, Brooks, Kristina M, Edmund V. Capparelli, Rungruengthanakit, Kittipong, Chakhtoura, Nahida   +41 more
core   +1 more source

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls

HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.
Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group   +11 more
wiley   +1 more source

Iatrogenic Cushing syndrome due to drug interaction between inhaled fluticasone and cobicistat [PDF]

, 2019
In this paper we report a case of iatrogenic Cushing syndrome due to a pharmacological interaction between fluticasone and cobicistat. Inhaled corticosteroids were previously thought to be safe, but increasing numbers of cases of iatrogenic Cushing ...
Monge, Elisa, Colombo, Valeria, Giacomelli, Andrea   +2 more
core  

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications

, 2016
Nearly all HIV PIs and the integrase inhibitor elvitegravir require a pharmacokinetic enhancer in order to achieve therapeutic plasma concentrations at the desired dose and frequency. Whereas ritonavir has been the only available pharmacokinetic enhancer
Back, David, Marzolini, C, Gibbons, Sara, Khoo, S, Marzolini, Catia, Back, D, Khoo, Saye, Gibbons, S   +7 more
core   +1 more source